Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team

Published:2019-07-16 Issue:4 Volume:124 Page:551-553
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Murphy Declan G.¹²,Hofman Michael S.²³,Azad Arun⁴,Violet John⁵,Hicks Rodney J.²³,Lawrentschuk Nathan¹⁶

Affiliation:

1. Division of Cancer Surgery; Peter MacCallum Cancer Centre; Melbourne Vic. Australia

2. Sir Peter MacCallum Department of Oncology; University of Melbourne; Melbourne Vic. Australia

3. Molecular Imaging and Nuclear Medicine Therapeutics; Peter MacCallum Cancer Centre; Melbourne Vic. Australia

4. Division of Medical Oncology; Peter MacCallum Cancer Centre; Melbourne Vic. Australia

5. Division of Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Vic. Australia

6. Department of Surgery; Austin Hospital; University of Melbourne; Heidelberg Vic. Australia

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14814/fullpdf

Reference7 articles.

1. Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre-impact on clinical decision-making and implications for patient inclusion;Rao;BJU Int,2014

2. Implementation rates of uro-oncology multidisciplinary meeting decisions;Kinnear;BJU Int,2017

3. Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer;Murphy;BJU Int,2017

4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol;Hofman;BJU Int,2018

5. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET imaging: Phase 1 study of (68)Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer;Hofman;J Nucl Med,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Care by Committee to be Superseded by Personal Physician–Patient Partnership Informed by Artificial Intelligence;Cancer Biotherapy and Radiopharmaceuticals;2023-10-01

2. Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives;Cancers;2023-09-27

3. Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens;European Urology Open Science;2023-08

4. Next generation radiotheranostics promoting precision medicine;Annals of Oncology;2023-06

5. Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review;Therapeutic Advances in Medical Oncology;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3